About recordati spa - RCDTF
Recordati SpA engages in the research, development, manufacture, and marketing of pharmaceuticals. It operates through the Specialty and Primary Care, and Rare Diseases segments. The Specialty and Primary Care segment includes pharmaceutical chemical operations. The company was founded by Giovanni Recordati in 1926 and is headquartered in Milan, Italy.
RCDTF At a Glance
Recordati SpA
Via Matteo Civitali, 1
Milan, Milan 20148
| Phone | 39-02-48787-1 | Revenue | 2.53B | |
| Industry | Pharmaceuticals: Major | Net Income | 450.53M | |
| Sector | Health Technology | 2024 Sales Growth | 12.509% | |
| Fiscal Year-end | 12 / 2025 | Employees | 4,583 | |
| View SEC Filings |
RCDTF Valuation
| P/E Current | 26.598 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 23.994 |
| Price to Sales Ratio | 4.325 |
| Price to Book Ratio | 5.608 |
| Price to Cash Flow Ratio | 17.77 |
| Enterprise Value to EBITDA | 14.751 |
| Enterprise Value to Sales | 5.209 |
| Total Debt to Enterprise Value | 0.195 |
RCDTF Efficiency
| Revenue/Employee | 552,660.425 |
| Income Per Employee | 98,305.227 |
| Receivables Turnover | 3.909 |
| Total Asset Turnover | 0.508 |
RCDTF Liquidity
| Current Ratio | 1.605 |
| Quick Ratio | 1.06 |
| Cash Ratio | 0.347 |
RCDTF Profitability
| Gross Margin | 68.342 |
| Operating Margin | 28.181 |
| Pretax Margin | 23.368 |
| Net Margin | 17.788 |
| Return on Assets | 9.042 |
| Return on Equity | 23.773 |
| Return on Total Capital | 10.012 |
| Return on Invested Capital | 11.957 |
RCDTF Capital Structure
| Total Debt to Total Equity | 133.477 |
| Total Debt to Total Capital | 57.169 |
| Total Debt to Total Assets | 48.387 |
| Long-Term Debt to Equity | 116.789 |
| Long-Term Debt to Total Capital | 50.022 |